Phase 2/3 Study of Bardoxolone Methyl in Treating Alport Syndrome-related CKD Gets Underway
Screening has begun in people with chronic kidney disease (CKD) caused by Alport syndrome, who are looking to take part in a Phase 2/3 clinical trial evaluating the efficacy of bardoxolone methyl, a therapy being developed by Reata Pharmaceuticals. The two-part study, called CARDINAL (NCT03019185) will assess the safety, tolerability, and…